17-01-2013

OBN announced changes to the OBN Board of Directors. Dr Steven Lee is reluctantly standing down as Chairman and his place will be taken by David Laskow-Pooley. Congratulating David on his appointment Steven said that “after 6 years as Chairman and with my business interests becoming ...

more

10-01-2013

Heptares Therapeutics announced they have signed an agreement with Cubist Pharmaceuticals, Inc. to collaborate on the research and discovery of new medicines targeting G protein-coupled receptors (GPCRs), which are membrane proteins involved in a broad range of biological processes and ...

more

09-01-2013

Prosonix has received a grant worth up to £1.3M from the Biomedical Catalyst. The grant will provide matched-funding support for the pre-clinical development of the Company’s Multi-component particle™ (MCP™) platform as a basis for future combination respiratory medicines. The £180M ...

more

08-01-2013

arGEN-X announced the initiation of a Phase Ib first-in-man cancer study with ARGX-110, its first SIMPLE Antibody™ program to enter the clinic in just three years from initiation of discovery. ARGX-110 is a first-in-class CD70-targeting monoclonal antibody that addresses both known mechanisms ...

more

14-12-2012

Clavis Pharma ASA announces data from its Phase II clinical trial with elacytarabine in combination with idarubicin. The trial enrolled patients with early stage acute myeloid leukaemia (AML), for whom cytarabine-containing first-course chemotherapy has failed. The results found that ...

more

07-12-2012

Prosonix announced the election of Dr Ken Cunningham as Non-executive Chairman. He replaces Dr Jim Philips, who has been Chairman of the Company since 2007, and is retiring from the Board of Directors.Dr Cunningham was elected to the Board of Prosonix as a Non-executive Director in September ...

more

Consortium supported with over €20 million funding from EU Innovative Medicines Initiative and big pharma

04-12-2012

Heptares Therapeutics is joining a group of European academic and industry researchers known as the ‘K4DD’ (‘Kinetics for Drug Discovery’) Consortium to investigate binding kinetics or ‘kinotypic’ properties of drug-receptor complexes. The five-year program will focus on important drug target ...

more

30-11-2012

Genzyme, a Sanofi Company, announced the appointment of Brendan Martin as General Manager for UK and Ireland. Brendan will be responsible for all Genzyme’s commercial activities in the UK and Ireland and will report to Robin Kenselaar, Head of Genzyme EMEA.Brendan joined Genzyme in 2002 and ...

more

30-11-2012

Nestlé Health Science SA, a fully-owned subsidiary of Nestlé SA, and Chi-Med, announced that they have agreed to form a 50/50 joint venture to be named Nutrition Science Partners Limited (“NSP”).The purpose of NSP is to research, develop, manufacture and market worldwide novel medicines and ...

more

26-11-2012

Cardio3 BioSciences (C3BS) announced it has received authorization from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C3BS-CQR-1 in Belgium. This represents a ...

more